SCHEMBL320859

SCHEMBL320859

COc1ccc(CN(c2ncns2)S(=O)(=O)c2ccc(Sc3ccccc3F)c(C#N)c2)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 15/20 0.43
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SLC22A12 Q96S37 2/20 0.35
AVPR2 P30518 1/20 0.34
OXTR P30559 1/20 0.34
AVPR1A P37288 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
HIF1A Q16665 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14892116 0.93 SCN9A (0.47) SCN9AMEN1KMT2ASLC22A12AVPR2
SCHEMBL14891037 0.88 SCN9A (0.44) SCN9ASLC22A12AVPR2OXTRAVPR1A
SCHEMBL319158 0.88 SCN9A (0.45) SCN9ASLC22A12
SCHEMBL31093304 0.88 SCN9A (0.45) SCN9ASLC22A12
SCHEMBL319879 0.88 SCN9A (0.43) SCN9ASLC22A12AVPR2OXTRAVPR1A
SCHEMBL320220 0.87 SCN9A (0.40) SCN9ACYP3A4CYP2C9
SCHEMBL16229831 0.85 SCN9A (0.41) SCN9AMEN1KMT2ASLC22A12AVPR2
SCHEMBL319485 0.84 SCN9A (0.45) SCN9ASLC22A12AVPR2OXTRAVPR1A
SCHEMBL16109346 0.81 SCN9A (0.48) SCN9AMEN1KMT2AALDH1A1HIF1A
SCHEMBL319172 0.81 SCN9A (0.48) SCN9ACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096558-B2 N-sulfonylbenzamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2590957-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-12 EP disclosed
EP-2590957-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-15 EP disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012004714-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109696-A1 Chemical Compounds SCN1A, SCN7A, SCN1B SCN9A 10/4885MEN1 2335/4885KMT2A 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.